

Supplementary

Table S1 List of HCC-causing HubGs-sets that were published in different articles

References	In vivo and in vitro experimentally validated (yes/no)	HubGs-sets	HubGs that were published in at least nine articles
(23)	Yes	CCNB1, CDK1, CDC20, PTTG1, CCNA2, TTK	CCNB1, CDK1, CDC20, TOP2A, CCNB2, BUB1B, CCNA2, PRC1
(111)	Yes	PPAT, YWHAB, NOL10	
(112)	No	TOP2A, NDC80, CDK1, CCNB1, KIF11, BUB1, CCNB2, CCNA2, TTK	
(113)	No	BIRC5, FOXM1, CENPA, KIF4A, DTYMK, PRC1, IGF2BP3, KIF2C, TRIP13, TPX2	
(101)	Yes	JUN, PIK3R1, STAT3, E2F2, E2F3, NRAS	
(114)	Yes	AURKA, KIF5B, RHOA	
(115)	No	MCM6, MCM3, UBE2C, RRM2, RFC4, TOP2A, MCM2, CDK1, PRIM1, CCNB1, HMMR, CDC20, CCNA2, NEK2, NDC80, DLGAP5, KIF11	
(116)	No	CDK1, CCNB1, AURKA, CCNA2, KIF11, BUB1B, TOP2A, TPX2, HMMR, CDC45	
(94)	No	TOP2A, NDC80, FOXM1, HMMR, KNTC1, PTTG1, FEN1, RFC4, SMC4, PRC1	
(16)	No	FOXM1, AURKA, CCNA2, CDKN3, MKI67, EZH2, CDC6, CDK1, CCNB1, TOP2A	
(117)	Yes	SPINK1, TXNRD1, LCAT, PZP	
(95)	No	CDC20, CCNB2, NCAPG, ASPM and NUSAP1	
(118)	No	TOP2A, CCNB2, PRC1, RACGAP1, AURKA, CDKN3, NUSAP1, CDCA5, ASPM, NCAPG	
(119)	Yes	CCNB2, NUSAP1, TK1	
(20)	No	CDK1, CCNB1, CCNB2, MAD2L1, TOP2A	
(120)	No	CYP3A4, UGT1A6, AOX1, UGT1A4, UGT2B15, CDK1, CCNB1, MAD2L1, CCNB2, CDC20	
(71)	Yes	CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, RFC4	
(121)	No	DTL, CDK1, CCNB1, RACGAP1, ECT2, NEK2, BUB1B, PBK, TOP2A, ASPM, HMMR, RRM2, CDKN3, PRC1, ANLN	
(122)	No	CDKN3, CDK1, CCNB1, TOP2A, CCNA2, CCNB2, PRC1, RRM2	
(123)	No	TTK, NCAPG, TOP2A, CCNB1, CDK1, PRC1, RRM2, UBE2C, ZWINT, CDKN3, AURKA, RACGAP1	
(124)	Yes	CDC20, TOP2A, RRM2, UBE2C, AOX1	
(72)	No	CCNB1, CDC20, CDK1, BUB1B, CCNA2, NUSAP1, UBE2C, ZWINT	
(21)	No	CDC20, CDK1, MAD2L1, BUB1, BUB1B, CCNB1, CCNA2	
(125)	No	CHGA, RAET1E, FGF9, GIP, NR0B1, IL20RA, ESRRG and GNRH2	
(22)	No	CCNB1, CCNA2, CCNB2, NCAPG, PBK, NUSAP1, AURKA, ZWINT, PRC1, KIF4A	
(126)	No	CDC20, BUB1B, KIF11, TTK, EZH2, ZWINT, NDC80, TPX2, MELK, KIF20A	
(127)	No	CCNB1, CDK1, RRM2, BUB1B	
(128)	Yes	CNIH4, SOX4, SPP1, SORBS2, CCL19	
(129)	No	CSE1L, CSTB, MTHFR, DAGLA, MMP10, GYS2	
(130)	Yes	CD163, EHHADH, KIAA0101, SLC16A2, SPP1, THBS4	
(131)	No	HAO1, SCL27A2, DAO, ABAT, PCK2	
(132)	No	PLK1, CDC20, HSP90AA1, CHEK1, HDAC1, NDC80	
(133)	No	CDK1, CCNB1, CCNB2, BUB1, KIF11	
(134)	Yes	BIRC5, CDC20, CCNB1, BUB1B, MAD2L1, CDK1	
(135)	No	CDC45, CENPA, MCM10, MELK, CDC20, ASF1B, FANCD2, NCAPH	
(136)	No	HDAC1, BIRC5, SPP1, STC2, NR6A1	
(137)	Yes	UBE2T, CYP3A4	
(138)	No	MCM3, TRMT6, AURKA, CDC20, TOP2A, ECT2, TK1, MCM2, FEN1, NCAPD2, KPNA2	
(139)	No	SOX4, STK39, TARBP1, TDRKH	
(140)	No	OIP5, ASPM, NUSAP1, UBE2C, CCNA2, KIF20A	
(141)	No	CDKN3, ZWINT, KIF20A, NUSAP1, HMMR, DLGAP5	
(142)	No	CDK1, CDC20, CCNB1, CENPF, MAD2L	
(143)	No	GMPS, ACACA, ALB, TGFB1, KRAS, ERBB2, BCL2, EGFR, STAT3, CD8A	
(144)	Yes	SERPINA1, IGFBP1, KNG1, TIMP1, APOA1, SPP1, IGFBP3, FBN1, VCAN, MATN3, STC2, SERPINC1, APOB	
(145)	No	CDKN3, CYP2C9, LCAT	
(146)	Yes	RELN, KCNJ10, NCAM1	
(147)	No	ZWINT, CENPA, RACGAP1, PLK1, NCAPG, OIP5, CDCA8, PRC1, CDK1	
(148)	No	CEP55, DEPDC1, KIF23, CLSPN, MYBL2, RACGAP1	
(149)	No	BMP4, PLCB1, PRKG2ITGA2, KDM6B, SPINK6, POU3F4 GLI1, MYC, CSNK2A1, POTEF, HSF1, SCNN1A	
(150)	No	TTK, BUB1, CYP3A4, NR1I2, CYP8B1	
(151)	No	CDK1, HMMR, PTTG1, TTK	
(70)	Yes	BUB1B, CCNB1, CCNB2, CDC20, CDK1, MAD2L1, RRM2	
(152)	No	AURKA, BUB1B, TOP2A, MAD2L1, CCNA2, CCNB1, BUB1, KIF11, CDK1, CCNB2, TPX2	
(153)	No	TOP2A, CDC20, PTTG1, CDC45, CCNB2, PRC1, KIF20A, SF3B4, HSP90AB1, FOXD2, PLOD3, CCT3, SETDB1, VPS45, SPDL1, RACGAP1, MED24, KIAA0101, ZNF282, USP21	
(154)	Yes	OP2A, ESR1, AURKA, KMO, CDKN3, ALDH8A1, CYP2C8, PRC1, NCAPG, CCNB	
(155)	No	HES5, KITLG, METTL3, PSMD1, RAB10, TCOF1, YTHDF2, ZC3H13	
(156)	Yes	BASP1, SRD5A2	
(157)	Yes	MCM7, UBE2L3, PPIA, CXCL12, ASS	
(158)	Yes	ADAR, PSMD4, D9SVA, CCT3, GBAP, RDBP, CSR2P, IL7R	

HCC, hepatocellular carcinoma; HubGs, hub differentially expressed genes.

Table S2 List of anti-HCC related 157 meta-drug agents

List of anti-HCC related meta-drug agents	References
Acriflavine	Suggested by Lee <i>et al.</i> (159)
Cisplatin, etoposide, bleomycin, cisplatin, vincristine, methotrexate, bleomycin, dactinomycin, cyclophosphamide, etoposide	Suggested by Whelan <i>et al.</i> (25)
CA4-P, vincristine	Suggested by Aboubakr <i>et al.</i> (160)
ε-viniferin, vincristine	Suggested by Özdemir <i>et al.</i> (161)
Tacrolimus, mycophenolate, sirolimus	Suggested by Chinnakotla <i>et al.</i> (162)
Mycophenolate mofetil, sirolimus, tacrolimus	Suggested by Lee <i>et al.</i> (163)
Sirolimus	Suggested by Wang <i>et al.</i> (164)
Paclitaxel, tamoxifen, fluorouracil, ethinyl estradiol, doxorubicin, vorinostat, dabrafenib, sulfinpyrazone, teniposide, etoposide, vincristine, doxorubicin, norfloxacin, valrubicin, levofloxacin, enoxacin, daunorubicin, ofloxacin, pefloxacin, amsacrine, podofilox, dextrazoxane, mitoxantrone, lomefloxacin, epirubicin, dactinomycin, finafloxacin, idarubicin, hydroquinone	Suggested by Chen <i>et al.</i> (16)
Atezolizumab, avastin (bevacizumab), bevacizumab, cabometyx (cabozantinib-S-malate), cabozantinib-S-malate, cyramza (ramucirumab), infigratinib phosphate, keytruda (pembrolizumab), lenvatinib mesylate, lenvima (lenvatinib mesylate), nexavar (sorafenib tosylate), nivolumab, opdivo (nivolumab), pemazyre (pemigatinib), pembrolizumab, pemigatinib, ramucirumab, regorafenib, sorafenib tosylate, stivarga (regorafenib), tecentriq (atezolizumab), truseltiq (infigratinib phosphate)	Suggested on the NCI webpage (165)
3-CI-AHPC, ABT-199, ABT-737, AT13387, AZD1480, AZD7762, BI-2536, BIX-01294, BRD-K01737880, BRD-K66453893, RD-K70511574, CAY10618, CCT036477, CD-437, CHM-1, COL-3, FQI-1, GMX-1778, GSK-J4, SK461364, SK525762A, GW-843682X, HLI 373, I-BET151, JQ-1, KPT185, KU-60019, LRRK2-IN-1, LY-2157299, LY-2183240, ML239, ML311, MST-312, Merck60, NSC48300, NSC632839, NSC95397, NVP-231, NVP-BSK805, OSI-930, PF-184, PF-573228, PL-DI, PRIMA-1, PX-12, RITA, SB-225002, SB-743921, SCH-79797, SNX-2112, STF-31, TG-101348, TW-37, YK 4-279, alisertib, alvocidib, apicidin, avrainvillamide, axitinib, barasertib, bardoxolone methyl, belinostat, brivanib, ceranib-2, chlorambucil, ciclopirox, clofarabine, crizotinib, cucurbitacin I, curcumin, cytarabine hydrochloride, daporinad, decitabine, dinaciclib, docetaxel, doxorubicin, elocalcitol, entinostat, epigallocatechin-3-monogallate, etoposide, fluorouracil, gemcitabine, indisulam, isoevodiamine, isoliquiritigenin, leptomycin B, linifanib, manumycin A, marinopyrrole A, masitinib, methotrexate, methylstat, mitomycin, nakiterpiosin, narciclasine, navitoclax, necrosulfonamide, neopeltolide, nutlin-3, obatoclax, omacetaxine mepesuccinate, ouabain, paclitaxel, panobinostat, parbendazole, pazopanib, pevonedistat, phloretin, pifithrin-mu, piperlongumine, rigosertib, serdemetan, sotрастaurин, tacedinaline, teniposide, tivantinib, topotecan, tozasertib, triazolothiadiazine, tubastatin A, vincristine, vorinostat	Detected by the GSCALite: a web server based on the proposed tHubGs (166)

HCC, hepatocellular carcinoma; NCI, National Cancer Institute.

Table S3 The top 20 significantly (P_{adj} value <0.05) enriched GO functions by HubGs involving tHubGs with HCC

Term ID	Term name	P_{adj} value	Count	HubGs
MF				
GO:0097367	Carbohydrate derivative binding	2.69E-10	58	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, HMMR, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, APOB, ASS, BMP4, CDC6, CHEK1, CSNK2A1, DTYMK, EGFR, ERBB2, FB1N, FG9, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KNG1, KRAS, MCM6, MCM7, MKI67, NRAS, PCK2, PPIA, PRIM1, RAB10, RHOA, SERPINC1, SMC4, STK39, TK1, TRIP13, UBE2L3, VCAN
GO:0036094	Small molecule binding	1.74E-09	59	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, AOX1, CCT3, CYP3A4, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ABAT, ACACA, ALB, APOA1, ASS, CDC6, CHEK1, CSNK2A1, CYP8B1, DAO, DTYMK, EGFR, EHHADH, ERBB2, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, PL0D3, PRIM1, RAB10, RHOA, SMC4, STK39, TK1, TRIP13, TXNRD1, UBE2L3
GO:0005515	Protein binding	1.74E-09	174	CCNB1, CDK1 ¹ , CDC20 ¹ , TOP2A ¹ , CCNB2 ¹ , BUB1 ¹ , CCNA2, PRC1, AURKA ¹ , CDKN3, RRM2, MAD2L1, NUSAP1, RACGAP1, TTK, ZWINT, KIF11, NCAPG, UBE2C, BUB1, HMMR, NDC80, ASPM, KIF20A, PTTG1, SPP1, TPX2, BIRC5 ¹ , CENPA, FOXM1, RFC4, AOX1, CCT3, CDC45, CDC5, CYP3A4, DLGAP5, EZH2, HDAC1, KIF4A, LCAT, MCM2, MCM3, MELK, NEK2, OIP5, PBK, PLK1 ¹ , SOXA4, STAT3, STC2, ABAT, ACACA, ADAR, ALB, ANLN, APOA1, APOB, ASFB1, ASS, BASP1, BCL2, BMP4, CCL19, CD163, CD8A, CDC6, CDA8, CENPF, CEP55, CHEK1, CLSPN, CNIH4, CSE1L, CSNK2A1, CSR2, CSTB, CXCL12, DAGLA, DAO, DEPDCl, DTL, E2F2, E2F3, ECT2, EGFR, EHHADH, ERBB2, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MET24, MKI67, MYBL2, MYC, NCAM1, NCAPH, NOL10, NR0B1, NR12, NR6A1, NRAS, PCK2, PIK3R1, PLCB1, PL0D3, POTEF, PPIA, PRIM1, PSMD1, PSMD4, PZP, RAB10, RAET1E, RELA, RHOA, SCNN1A, SERPINC1, SETDB1, SF3B4, SMC4, SORBS2, SPDL1, SPINK1, SPINK6, SRD5A2, STK39, TCOF1, TDRKH, TGFB1, THBS4, TIMP1, TK1, TRIP13, TXNRD1, UBE2L3, UGT1A4, UGT1A6, USP1, VCAN, VPS45, YTHDF2, YWHAB, ZC3H13
GO:0043168	Anion binding	1.83E-09	57	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , RACGAP1, TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, AOX1, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ABAT, ACACA, ALB, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, EHHADH, ERBB2, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, PL0D3, RAB10, RHOA, SMC4, STK39, TK1, TRIP13, TXNRD1, UBE2L3
GO:0019899	Enzyme binding	1.83E-09	52	CCNB1, CDC20 ¹ , TOP2A ¹ , CCNA2, PRC1, AURKA ¹ , RACGAP1, KIF11, UBE2C, KIF20A, TPX2, BIRC5 ¹ , FOXM1, CYP3A4, DLGAP5, EZH2, HDAC1, KIF4A, LCAT, MCM2, MCM3, MELK, NEK2, OIP5, PBK, PLK1 ¹ , SOXA4, STAT3, STC2, ABAT, APOA1, APOB, BCL2, CDC6, CSE1L, CSTB, ECT2, EGFR, EHHADH, ERBB2, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, PRIM1, PZP, RHOA, SERPINA1, SERPINC1, SPDL1, STK39, TIMP1, UGT1A4, UGT1A6, YWHAB
GO:1901265	Nucleoside phosphate binding	2.46E-09	53	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, AOX1, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, EHHADH, ERBB2, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, PRIM1, RAB10, RHOA, SMC4, STK39, TK1, TRIP13, TXNRD1, UBE2L3
GO:0000166	Nucleotide binding	2.46E-09	53	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, AOX1, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, EHHADH, ERBB2, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, PRIM1, RAB10, RHOA, SMC4, STK39, TK1, TRIP13, TXNRD1, UBE2L3
GO:0032553	Ribonucleotide binding	1.30E-08	48	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, ERBB2, GMPS, HA01, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, PRIM1, RAB10, RHOA, SMC4, STK39, TK1, TRIP13, UBE2L3
GO:0005524	ATP binding	2.12E-08	41	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, ERBB2, GMPS, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, MCM6, MCM7, MKI67, SMC4, STK39, TK1, TRIP13, UBE2L3
GO:0035639	Purine ribonucleoside triphosphate binding	2.57E-08	46	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, ERBB2, GMPS, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, SMC4, STK39, TK1, TRIP13, UBE2L3
GO:0032559	Adenyl ribonucleotide binding	5.94E-08	41	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, ERBB2, GMPS, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, SMC4, STK39, TK1, TRIP13, UBE2L3
GO:0042802	Identical protein binding	6.04E-08	49	TOP2A ¹ , PRC1, RRM2, MAD2L1, TTK, NDC80, BIRC5 ¹ , AXO1, OIP5, PLK1 ¹ , STAT3, STC2, ABAT, ACACA, ALB, APOA1, ASS, BCL2, CENPF, CEP55, CSNK2A1, DAO, ECT2, EGFR, ERBB2, ESRRG, FBN1, HSF1, HSP90AA1, HSP90AB1, JUN, KIF6A, KRAS, MCM6, MCM7, MKI67, SMR21, CENPF, SERPINA1, SERPINC1, SORBS2, STK39, TXNRD1, UBE2L3
GO:0030554	Adenylyl nucleotide binding	6.04E-08	41	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, ERBB2, GMPS, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, PRIM1, RAB10, RHOA, SMC4, STK39, TK1, TRIP13, UBE2L3
GO:0032555	Purine ribonucleotide binding	6.04E-08	46	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, ERBB2, GMPS, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, SMC4, STK39, TK1, TRIP13, UBE2L3
GO:0017076	Purine nucleotide binding	7.12E-08	46	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, CCT3, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ACACA, ASS, CDC6, CHEK1, CSNK2A1, DAO, DTYMK, EGFR, ERBB2, GMPS, HSP90AA1, HSP90AB1, KCNJ10, KIF23, KIF2C, KIF5B, KRAS, MCM6, MCM7, MKI67, MTHFR, NRAS, PCK2, RAB10, RHOA, SMC4, STK39, TK1, TRIP13, UBE2L3
GO:0098772	MF regulator activity	1.22E-07	46	CCNB1, CDC20 ¹ , CCNB2 ¹ , CCNA2, RACGAP1, PTTG1, SPP1, TPX2, BIRC5 ¹ , STC2, APOA1, BCL1, BMP4, CCL19, CSTB, CXCL12, DEPDCl, ECT2, EGFR, FBN1, GFG9, IPN, GMPS, HSP90AA1, HSP90AB1, IGFBP3, JUN, KITLG, KNG1, KRAS, NRAS, PIK3R1, PLCB1, PSMD1, PZP, RAB10, RHOA, SERPINA1, SERPINC1, SPINK1, SPINK6, TGFb1, THBS4, TIMP1, UBE2L3, YWHAB
GO:0043167	Ion binding	6.56705E-06	90	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , RRM2, RACGAP1, TTK, KIF11, UBE2C, BUB1, KIF20A, BIRC5 ¹ , AXO1, CCT3, CYP344, HDAC1, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ABAT, ACACA, ADAR, ALB, APOA1, ASS, BCL2, CENPF, CEP55, CSNK2A1, DAO, ECT2, EGFR, ERBB2, ESRRG, FBN1, HSF1, HSP90AA1, HSP90AB1, JUN, KIF6A, KRAS, MCM6, MCM7, MKI67, MTHFR, NR12, NR6A1, NRAS, PCK2, PL0D3, PPAT, PRIM1, RAB10, RELN, RHOA, SETDB1, SMC4, STK39, TK1, TRIP13, TXNRD1, UBE2L3, USP21, VCAN, ZC3H13, ZNF282
GO:0008017	Microtubule binding	1.27186E-05	14	PRC1, NUSAP1, RACGAP1, KIF11, KIF20A, TPX2, BIRC5 ¹ , AXO1, OIP5, PLK1 ¹ , STAT3, STC2, ABAT, ACACA, ALB, APOA1, ASS, BCL2, CENPF, CEP55, CSNK2A1, DAO, ECT2, EGFR, ERBB2, ESRRG, FBN1, HSF1, HSP90AA1, HSP90AB1, JUN, KIF6A, KRAS, MCM6, MCM7, MKI67, SMR21, CENPF, SERPINA1, SERPINC1, SORBS2, TGFb1, TK1, TRIP13, UGT1A4, UGT1A6, YWHAB
GO:0097159	Organic cyclic compound binding	1.93853E-05	103	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , NUSAP1, TTK, KIF11, UBE2C, BUB1, KIF20A, RFC4, AOX1, CCT3, CDC45, CYP3A4, DLGAP5, EZH2, HDAC1, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , SOXA4, STAT3, STC2, ABAT, ACACA, ADAR, ALB, APOA1, ASS, BASP1, BCL2, CDC6, CHEK1, CLSPN, CSNK2A1, CSTB, CYP29, CYP8B1, DAO, DTYMK, E2F2, E2F3, EGFR, EHHADH, ERBB2, ESRRG, FBN1, FOXP2, GMPS, HA01, HSP90AA1, HSP90AB1, IGFBP3, JUN, KIF6A, KRAS, MCM6, MCM7, MKI67, MYBL2, MYC, NCAPL1, PLCB1, RHOA, SM4, SPDL1, TGFb1, TRIP13, UBE2L3
GO:1901363	Heterocyclic compound binding	2.27949E-05	102	CDK1 ¹ , TOP2A ¹ , BUB1 ¹ , AURKA ¹ , NUSAP1, TTK, KIF11, UBE2C, BUB1, KIF20A, BIRC5 ¹ , AXO1, CCT3, CYP344, HDAC1, KIF4A, MCM2, MCM3, MELK, NEK2, PBK, PLK1 ¹ , ABAT, ACACA, ADAR, ALB, APOA1, ASS, BCL2, CENPF, CEP55, CSNK2A1, CSTB, CYP29, CYP8B1, DAO, DTYMK, E2F2, E2F3, EGFR, EHHADH, ERBB2, ESRRG, FBN1, FOXP2, GMPS, HA01, HSP90AA1, HSP90AB1, JUN, KIF6A, KRAS, MCM6, MCM7, MKI67, MYBL2, MYC, NCAPL1, PLCB1, RHOA, SM4, SPDL1, TGFb1, TRIP13, UBE2L3, YWHAB
BP				
GO:1903047	Mitotic cell cycle process	4.70E-41	64	CCNB1, CDK1 ¹ , CDC20 ¹ , CCNB2 ¹ , BUB1 ¹ , CCNA2, PRC1, AURKA ¹ , CDKN3, RRM2, MAD2L1, NUSAP1, RACGAP1, TTK, ZWINT, KIF11, NCAPG, UBE2C, BUB1, NDC80, KIF20A, PTTG1, TPX2, BIRC5 ¹ , CENPA, FOXM1, CDC45, CDC5, DLGAP5, EZH2, KIF4A, MCM2, MCM3, MELK, NEK2, PLK1 ¹ , ANLN, BCL2, BMP4, CDC6, CDC8, CENPF, CEP55, CHEK1, CLSPN, DTL, E2F2, ECT2, EGFR, FANCD2, FBN1, KIF23, KIF2C, KNTC1, MCM6, MCM7, MKI67, MYBL2, MYC, NCAPL1, PLCB1, RHOA, SM4, SPDL1, TGFb1, TRIP13, UBE2L3
GO:0000278	Mitotic cell cycle	1.47E-38	66	CCNB1, CDK1 ¹ , CDC20 ¹ , CCNB2 ¹ , BUB1 ¹ , CCNA2, PRC1, AURKA ¹ , CDKN3, RRM2, MAD2L1, NUSAP1, RACGAP1, TTK, ZWINT, KIF11, NCAPG, UBE2C, BUB1, NDC80, KIF20A, PTTG1, TPX2, BIRC5 ¹ , CENPA, FOXM1, CDC45, CDC5, DLGAP5, EZH2, KIF4A, MCM2, MCM3, MELK, NEK2, PLK1 ¹ , ANLN, BCL2, BMP4, CDC6, CDC8, CENPF, CEP55, CHEK1, CLSPN, CSNK2A1, CSTB, CYP29, CYP8B1, DAO, DTYMK, E2F2, E2F3, EGFR, EHHADH, ERBB2, ESRRG, FBN1, FOXP2, GMPS, HA01, HSP90AA1, HSP9

References

111. Hu X, Bao M, Huang J, et al. Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. *Front Oncol* 2020;10:541479.
112. Zeng L, Fan X, Wang X, et al. Bioinformatics Analysis based on Multiple Databases Identifies Hub Genes Associated with Hepatocellular Carcinoma. *Curr Genomics* 2019;20:349-61.
113. Wang D, Liu J, Liu S, et al. Identification of Crucial Genes Associated With Immune Cell Infiltration in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis. *Front Genet* 2020;11:342.
114. Wang F, Xu X, Zhang N, et al. Identification and integrated analysis of hepatocellular carcinoma-related circular RNA signature. *Ann Transl Med* 2020;8:294.
115. Tang Y, Zhang Y, Hu X. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis. *Biomed Res Int* 2020;2020:4251761.
116. Zhang P, Feng J, Wu X, et al. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases. *Pathol Oncol Res* 2021;27:588532.
117. Zheng Y, Liu Y, Zhao S, et al. Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma. *Cancer Manag Res* 2018;10:6079-96.
118. Chen H, Wu J, Lu L, et al. Identification of Hub Genes Associated With Immune Infiltration and Predict Prognosis in Hepatocellular Carcinoma via Bioinformatics Approaches. *Front Genet* 2020;11:575762.
119. Liu L, Chen A, Chen S, et al. CCNB2, NUSAP1 and TK1 are associated with the prognosis and progression of hepatocellular carcinoma, as revealed by co-expression analysis. *Exp Ther Med* 2020;19:2679-89.
120. Liu J, Han F, Ding J, et al. Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis. *Biomed Res Int* 2021;2021:8849415.
121. Zhou Z, Li Y, Hao H, et al. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis. *Cell Transplant* 2019;28:76S-86S.
122. Wu M, Liu Z, Li X, et al. Analysis of potential key genes in very early hepatocellular carcinoma. *World J Surg Oncol* 2019;17:77.
123. Wu M, Liu Z, Zhang A, et al. Identification of key genes and pathways in hepatocellular carcinoma: A preliminary bioinformatics analysis. *Medicine (Baltimore)* 2019;98:e14287.
124. Tian D, Yu Y, Zhang L, et al. A Five-Gene-Based Prognostic Signature for Hepatocellular Carcinoma. *Front Med (Lausanne)* 2021;8:681388.
125. Ye D, Liu Y, Li G, et al. A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients. *Front Oncol* 2021;11:766072.
126. Chen X, Liao L, Li Y, et al. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. *Biomed Res Int* 2020;2020:7653506.
127. Sun Q, Liu P, Long B, et al. Screening of significant biomarkers with poor prognosis in hepatocellular carcinoma via bioinformatics analysis. *Medicine (Baltimore)* 2020;99:e21702.
128. Wang Z, Pan L, Guo D, et al. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma. *Cancer Med* 2021;10:3808-21.
129. Liu GM, Zeng HD, Zhang CY, et al. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. *Cancer Cell Int* 2019;19:138.
130. Wu D, Pan Y, Zheng X. Identification of hub genes-based predictive model in hepatocellular carcinoma by robust rank aggregation and regression analysis. *J Cancer* 2021;12:1884-93.
131. Song H, Ding N, Li S, et al. Identification of Hub Genes Associated With Hepatocellular Carcinoma Using Robust Rank Aggregation Combined With Weighted Gene Co-expression Network Analysis. *Front Genet* 2020;11:895.
132. Wang J, Li Y, Zhang C, et al. Characterization of diagnostic and prognostic significance of cell cycle-linked genes in hepatocellular carcinoma. *Transl Cancer Res* 2021;10:4636-51.
133. Shi Q, Meng Z, Tian XX, et al. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma. *Future Oncol* 2021;17:2193-208.

- 134.Jin B, Wang W, Du G, et al. Identifying hub genes and dysregulated pathways in hepatocellular carcinoma. *Eur Rev Med Pharmacol Sci* 2015;19:592-601.
- 135.Chen Z, Yu H, Wu L, et al. Identification and Validation of Hub Genes Predicting Prognosis of Hepatocellular Carcinoma. *Dig Surg* 2022;39:24-31.
- 136.Zhu Z, Song M, Li W, et al. Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma. *Front Oncol* 2021;11:695001.
- 137.Mao JX, Zhao YY, Dong JY, et al. UBE2T And CYP3A4: hub genes regulating the transformation of cirrhosis into hepatocellular carcinoma. *All Life* 2021;14:509-21.
- 138.Zhao Q, Zhang Y, Shao S, et al. Identification of hub genes and biological pathways in hepatocellular carcinoma by integrated bioinformatics analysis. *PeerJ* 2021;9:e10594.
- 139.Li J, Wang X, Yang J, et al. Identification of Hub Genes in Hepatocellular Carcinoma Related to Progression and Prognosis by Weighted Gene Co-Expression Network Analysis. *Med Sci Monit* 2020;26:e920854.
- 140.Li C, Xu J. Identification of Potentially Therapeutic Target Genes of Hepatocellular Carcinoma. *Int J Environ Res Public Health* 2020;17:1053.
- 141.Dai Q, Liu T, Gao Y, et al. Six genes involved in prognosis of hepatocellular carcinoma identified by Cox hazard regression. *BMC Bioinformatics* 2021;22:167.
- 142.Qiang R, Zhao Z, Tang L, et al. Identification of 5 Hub Genes Related to the Early Diagnosis, Tumour Stage, and Poor Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis. *Comput Math Methods Med* 2021;2021:9991255.
- 143.Zhang C, Peng L, Zhang Y, et al. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. *Med Oncol* 2017;34:101.
- 144.Jiang X, Zhang W, Li L, et al. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma. *Pathol Oncol Res* 2021;27:1609985.
- 145.Jiang CH, Yuan X, Li JF, et al. Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma. *J Transl Med* 2020;18:40.
- 146.Liu J, Hua P, Hui L, et al. Identification of hub genes and pathways associated with hepatocellular carcinoma based on network strategy. *Exp Ther Med* 2016;12:2109-19.
- 147.Li B, Pu K, Wu X. Identifying novel biomarkers in hepatocellular carcinoma by weighted gene co-expression network analysis. *J Cell Biochem* 2019;120:11418-31.
- 148.Pu Z, Zhu Y, Wang X, et al. Identification of Prognostic Biomarkers and Correlation With Immune Infiltrates in Hepatocellular Carcinoma Based on a Competing Endogenous RNA Network. *Front Genet* 2021;12:591623.
- 149.Zheng Y, Long J, Wu L, et al. Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing. *Oncotarget* 2017;8:60358-67.
- 150.Zhang R, Huang M, Wang H, et al. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion. *Pathol Oncol Res* 2021;27:597527.
- 151.Lei X, Zhang M, Guan B, et al. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis. *Hum Genomics* 2021;15:39.
- 152.Su Q, Li W, Zhang X, et al. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma. *Curr Pharm Biotechnol* 2023;24:1035-58.
- 153.Lin Y, Liang R, Ye J, et al. A twenty gene-based gene set variation score reflects the pathological progression from cirrhosis to hepatocellular carcinoma. *Aging (Albany NY)* 2019;11:11157-69.
- 154.Li C, Zhou D, Jiang X, et al. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker. *Gene* 2019;698:9-18.
- 155.Bai W, Cheng L, Xiong L, et al. Identification of Prognostic Genes in Hepatocellular Carcinoma. *Int J Gen Med* 2022;15:2895-904.
- 156.Moribe T, Iizuka N, Miura T, et al. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. *Int J Oncol* 2008;33:949-58.
- 157.Iizuka N, Tsunedomi R, Tamesa T, et al. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to

- genotype-C hepatitis B virus. *J Cancer Res Clin Oncol* 2006;132:473-81.
158. Midorikawa Y, Tsutsumi S, Taniguchi H, et al. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. *Jpn J Cancer Res* 2002;93:636-43.
159. Lee CJ, Yue CH, Lin YY, et al. Antitumor activity of acriflavine in human hepatocellular carcinoma cells. *Anticancer Res* 2014;34:3549-56.
160. Aboubakr EM, Taye A, Aly OM, et al. Enhanced anticancer effect of Combretastatin A-4 phosphate when combined with vincristine in the treatment of hepatocellular carcinoma. *Biomed Pharmacother* 2017;89:36-46.
161. Özdemir F, Akalin G, Şen M, et al. Towards novel anti-tumor strategies for hepatic cancer: ε -viniferin in combination with vincristine displays pharmacodynamic synergy at lower doses in HepG2 cells. *OMICS* 2014;18:324-34.
162. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. *Liver Transpl* 2009;15:1834-42.
163. Lee KW, Kim SH, Yoon KC, et al. Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial. *J Clin Med* 2020;9:3264.
164. Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2009;135:715-22.
165. National Cancer Institute. Drugs Approved for Liver Cancer. Available online: <https://www.cancer.gov/about-cancer/treatment/drugs/liver>
166. Liu CJ, Hu FF, Xia MX, et al. GSCALite: a web server for gene set cancer analysis. *Bioinformatics* 2018;34:3771-2.